This company listing is no longer active
PBP Stock Overview
Engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Probiotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.99 |
| 52 Week High | AU$3.03 |
| 52 Week Low | AU$2.16 |
| Beta | 0.47 |
| 1 Month Change | 2.23% |
| 3 Month Change | 5.85% |
| 1 Year Change | 12.22% |
| 3 Year Change | 40.14% |
| 5 Year Change | 91.35% |
| Change since IPO | 729.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | 1.1% |
| 1Y | 12.2% | -22.8% | 4.4% |
Return vs Industry: PBP underperformed the Australian Pharmaceuticals industry which returned 63.2% over the past year.
Return vs Market: PBP exceeded the Australian Market which returned 6.1% over the past year.
Price Volatility
| PBP volatility | |
|---|---|
| PBP Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: PBP has not had significant price volatility in the past 3 months.
Volatility Over Time: PBP's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Wes Stringer | www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
| PBP fundamental statistics | |
|---|---|
| Market cap | AU$242.34m |
| Earnings (TTM) | AU$8.69m |
| Revenue (TTM) | AU$221.22m |
27.9x
P/E Ratio1.1x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBP income statement (TTM) | |
|---|---|
| Revenue | AU$221.22m |
| Cost of Revenue | AU$154.96m |
| Gross Profit | AU$66.25m |
| Other Expenses | AU$57.57m |
| Earnings | AU$8.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 29.95% |
| Net Profit Margin | 3.93% |
| Debt/Equity Ratio | 52.5% |
How did PBP perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield65%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/18 18:32 |
| End of Day Share Price | 2024/06/18 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Probiotec Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Tang | Morgans Financial Limited |
| James Filius | Morgans Financial Limited |
| James Filius | Morgans Financial Limited |